( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...

Researchers have discovered a three-drug combination that enhances the generation of CAR-T cells, a type of cancer immunotherapy, and could improve CAR-T cell production for clinical treatments. The ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Anavex's financial health is stable with cash runway into 2028, but rising expenses are expected. Click here to find out why ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Frontotemporal dementia (FTD) is a rare and progressive form of dementia that primarily affects people between the ages of 40 ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...